Andere Sprachen Marinus Pharmaceuticals, Inc.

Aktien

A2QEUC

US56854Q2003

MRNS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
1.405 ^USD	-1.06%		+1.81%	-87.07%

17.04.	MARINUS PHARMACEUTICALS, INC. : Truist Securities behält die Bewertung Kaufen bei	ZM
16.04.	MARINUS PHARMACEUTICALS, INC. : Baird ist jetzt neutral	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Powell Comments, -2-	16.04.
Sector Update: Health Care Stocks Softer Late Afternoon	15.04.
Marinus Pharmaceuticals Shares Fall After Phase 3 Trial Interim Analysis of Ganaxolone	15.04.
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results	15.04.
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial	15.04.
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	05.04.
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review	28.03.
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review	27.03.
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) added to S&P Pharmaceuticals Select Industry Index	18.03.
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency	07.03.
UK Approves Marinus Pharmaceuticals' Ztalmy for Rare Genetic Disorder	07.03.
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	06.03.
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket	06.03.
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours	05.03.
Marinus Pharmaceuticals: Q4 Earnings Snapshot	05.03.
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
Marinus Pharmaceuticals : Corporate Overview Slide Deck	05.03.
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Posts Q4 Revenue $7.2M, vs. Street Est of $8.1M	05.03.
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	05.03.
Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024	05.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Marinus Pharmaceuticals, Inc.

Aktien

A2QEUC

US56854Q2003

MRNS

Andere Sprachen

Filter